Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Roche 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Roche 3Q

Pharmaceutical sales were up 2% attributed to Avastin, MabThera/Rituxan, Herceptin, Lucentis, Actemra/RoActemra and Xeloda.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Roche 3Q

3Q Revenues: $12.1 billion (+2%)

YTD Revenues: $37.0 billion (+3%)

Comments: Pharmaceutical sales were up 2% attributed to Avastin, MabThera/Rituxan, Herceptin, Lucentis, Actemra/RoActemra and Xeloda. Sales of cancer medicines were up 8% in the quarter. Revenues in the quarter were negatively impacted by lower demand for Tamiflu. Roche’s Diagnostics Division revenue was up 9% driven mainly by professional diagnostics and diabetes care.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters